Dyax's Threat to $630,000 Shire Drug Makes It a TargetMakiko Kitamura
Dyax Corp.’s promising treatment for a rare genetic disorder threatens Dublin-based Shire Plc’s fastest-growing medicine. That makes the $3.6 billion U.S. biotechnology company a potential takeover target.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.